|Other Names||Proto-oncogene vav, VAV1, VAV|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13853c was selected from the Center region of VAV1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation.|
|Tissue Location||Widely expressed in hematopoietic cells but not in other cell types|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this proto-oncogene is a member ofthe Dbl family of guanine nucleotide exchange factors (GEF) for theRho family of GTP binding proteins. The protein is important inhematopoiesis, playing a role in T-cell and B-cell development andactivation. This particular GEF has been identified as the specificbinding partner of Nef proteins from HIV-1. Coexpression andbinding of these partners initiates profound morphological changes,cytoskeletal rearrangements and the JNK/SAPK signaling cascade,leading to increased levels of viral transcription and replication.
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Hollmann, A., et al. Hematol Oncol 28(3):142-150(2010)Barda-Saad, M., et al. EMBO J. 29(14):2315-2328(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Kim, H.S., et al. Immunity 32(2):175-186(2010)
If you have any additional inquiries please email technical services at email@example.com.